{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Repsonse"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Not Assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Number of participants with tumor response using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm). PR is defined as at least a 30% decrease in the sum of diameter of target lesions. SD which is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.","groups":[{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle","id":"OG000","title":"Cohort A"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG001","title":"Cohort B"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.","id":"OG002","title":"Cohort C"}],"paramType":"NUMBER","populationDescription":"All participants in Part B who received at least one dose of study drug and had post-baseline tumor assessment.","reportingStatus":"POSTED","timeFrame":"Baseline through progressive disease (Up to 7.36 months)","title":"Number of Participants With Tumor Response","type":"SECONDARY","unitOfMeasure":"participants"}